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Abstract
Objectives To investigate patterns of self monitoring
of blood glucose concentration in diabetic patients
who use insulin and to determine whether frequency
of self monitoring is related to glycaemic control.
Setting Diabetes database, Tayside, Scotland.
Subjects Patients resident in Tayside in 1993›5 who
were using insulin and were registered on the
database and diagnosed with insulin dependent
(type 1) or non›insulin dependent (type 2) diabetes
before 1993.
Main outcome measures Number of glucose
monitoring reagent strips dispensed (reagent strip
uptake) derived from records of prescriptions. First
recorded haemoglobin A1c concentration in the study
period, and reagent strips dispensed in the previous 6
months.
Results Among 807 patients with type 1 diabetes, 128
(16%) did not redeem any prescriptions for glucose
monitoring reagent strips in the 3 year study period.
Only 161 (20%) redeemed prescriptions for enough
reagent strips to test glucose daily. The corresponding
figures for the 790 patients with type 2 diabetes who
used insulin were 162 (21%; no strips) and 131 (17%;
daily tests). Reagent strip uptake was influenced both
by age and by deprivation category. There was a direct
relation between uptake and glycaemic control for
258 patients (with recorded haemoglobin A1c
concentrations) with type 1 diabetes. In a linear
regression model the decrease in haemoglobin A1c
concentration for every extra 180 reagent strips
dispensed was 0.7%. For the 290 patients with type 2
diabetes who used insulin there was no such relation.
Conclusions Self monitoring of blood glucose
concentration is associated with improved glycaemic
control in patients with type 1 diabetes. Regular self
monitoring in patients with type 1 and type 2 diabetes
is uncommon.
Introduction
The importance of normoglycaemia for the subse›
quent prevention of diabetic complications is now rec›
ognised.1 2 Self monitoring of blood glucose has been
recommended as a technique for improving control of
blood glucose concentrations,3 and a common view is
that it should form part of an integrated treatment
programme.4 An American study in 1993, however,
showed that over two thirds of diabetic patients carried
out no self monitoring at all.5
In 1995 £42.6 million was spent on self monitoring
of glucose concentrations in the United Kingdom,6
despite increasing doubt about its benefits. Studies car›
ried out in selected clinic populations (children,7 young
people,8 elderly people9) or under experimental trial
conditions,10–13 or both, have shown that tests can be
inaccurate and unreliable, may not be interpreted by
patients correctly, and can cause psychological harm.6
We studied patterns of self monitoring and its effect on
glycaemic control in an unselected population of
diabetic patients who use insulin in Tayside, Scotland,
using data available through the DARTS/MEMO
collaboration.14 15 This was an observational outcomes
study, enabling the non›interventional investigation of
the effectiveness of glucose monitoring under real life,
non›experimental conditions.
Methods
The DARTS/MEMO collaboration has pioneered the
record linkage of healthcare data in the population of
Tayside, Scotland (estimated mid›year resident popula›
tion of 395 600 in 199516). By record linking independ›
ent data sources with the community health index
number (a unique patient identifier used for health›
care activity in Tayside) a population based register of
patients with diabetes in Tayside, known as DARTS
(diabetes audit and research in Tayside),15 has been
created and validated.17–19
This study was carried out among people who were
resident in Tayside (or who died) during the study
period (January 1993 to December 1995). Patients who
were diagnosed with type 1 diabetes before January
1993 were identified from the register, as were those
with type 2 diabetes who were using insulin during the
first 6 months of 1993 (and were presumed to be using
insulin thereafter).
Self monitoring of blood glucose
The number of blood glucose monitoring reagent
strips dispensed to patients during the study period
was determined from the MEMO dispensed prescrib›
ing database, a computerised record of all prescrip›
tions dispensed in community pharmacies in Tayside
since 1993.14 Patterns of use were investigated by sex,
age, and duration of diabetes. The Carstairs social dep›
rivation categories of the study patients, ranging from
category 1 (most affluent) to category 7 (least affluent)
and based on four census variables, were also
determined from details of the patients’ postcodes.20
Blood glucose control
Patients who had at least one glycated haemoglobin (A1c)
concentration recorded between July 1993 and Decem›
ber 1995 were identified. The numbers of reagent strips
that were dispensed to these patients during a 6 month
period before their first haemoglobin A1c measurements
were calculated. Linear regression models for patients
with type 1 and type 2 diabetes were constructed
separately, with haemoglobin A1c as the outcome and
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age, sex, duration of diabetes, and deprivation category
as covariates. The effect of body mass index (available for
70% and 75% of patients with type 1 and type 2 diabetes,
respectively) was also investigated. The analyses were
repeated in subgroups of patients who obtained at least
one pack of strips.
Costs and analysis
The total cost of the blood glucose test strips dispensed
was calculated with 1998 tariffs obtained from the
British National Formulary (number 35)21 (including the
pharmacist’s dispensing fee). All statistical analyses
were carried out with SPSS.
Results
Self monitoring of blood glucose
Among 367 051 Tayside residents there were 807
(0.2%) patients with type 1 diabetes and 5601 (1.5%)
with type 2 diabetes, 790 of whom were included in the
study (table 1). In total, 13 382 prescriptions for blood
glucose monitoring reagent strips were dispensed to
1307 of these patients during the 3 year period.
In those with type 1 diabetes, 128 (16%) of the 807
patients obtained no reagent strips at all. The 679
remaining patients obtained between 50 and 6220 strips
(between 0.05 and 5.68 strips a day). One hundred and
sixty one (20%) patients obtained more than 1095 strips
(equivalent to one a day), and only eight (1%) patients
obtained enough strips to measure at least four times
daily. In those with type 2 diabetes, 162 (21%) of the 790
study patients obtained no strips. The 628 remaining
patients obtained between 50 and 10 100 strips (that is,
between 0.05 and 9.2 strips a day), with 131 patients
(17%) obtaining more than 1095 strips.
Table 2 shows patterns of uptake of reagent strips
by sex, age, duration of diabetes, and deprivation
category. There was a particularly high uptake in
children with type 1 diabetes, which then decreased
sharply among young adults (15›24 years). Elderly
people were another group with low uptake. Analysis
by duration of diabetes showed a similar pattern, prob›
ably partly because of confounding by age. A pattern of
decreasing uptake with increasing age was also evident
among patients with type 2 diabetes. A trend of
decreasing uptake with increasing deprivation was evi›
dent, particularly among patients with type 2 diabetes.
Blood glucose control
There were 258 patients with type 1 diabetes who had
at least one valid haemoglobin A1c concentration
recorded (ranging from 4.2% to 17.4% of total haemo›
globin), of whom 152 had obtained at least one pack of
reagent strips in the previous 6 months. In a linear
regression model the total number of reagent strips
dispensed was a predictor of haemoglobin A1c concen›
tration (P < 0.001; table 3), with a decrease in
haemoglobin A1c concentration for every extra 180 test
strips dispensed (equivalent to one a day) of 0.7%. Sex
was the only other independent predictor of haemo›
globin A1c concentration (P = 0.002), with higher values
in female patients (table 3). In the subgroup of 152
patients (those who obtained at least one pack of strips
in the 6 month period) the relation between strip
uptake and haemoglobin A1c concentration was still
strong (regression coefficient − 0.672, P < 0.001).
There were 290 insulin users with type 2 diabetes
who had at least one valid haemoblobin A1c concentra›
tion recorded (ranging from 4.2% to 14.3%). In a linear
regression model none of the covariates, including the
number of strips dispensed (P = 0.357), were inde›
pendent predictors of haemoglobin A1c concentration
(table 4). Similarly, there were no associations in the
171 patients who obtained at least one pack of strips.
Cost
The total cost of the 7002 prescriptions for glucose
monitoring test strips dispensed to patients with type 1
diabetes was £155 912 (an average of £64.40 per patient
per year). The 6381 prescriptions for reagent strips
dispensed to patients with type 2 diabetes who used
insulin cost £134 907 (£56.92 per patient per year).
Discussion
Self monitoring of blood glucose
This study provides an insight into blood glucose
monitoring habits in all diabetic patients in Tayside
who used insulin and shows that many patients with
either type of diabetes did no testing at all. Less than
one fifth tested daily.
It is encouraging to note that large numbers of
strips were dispensed to children who are learning to
Table 1 Age and sex of patients with diabetes in study of self
monitoring of blood glucose concentration
Age
(years)
Type 1 diabetes (n=807) Type 2 diabetes (n=790)
Male Female Male Female
0›14 29 42 — —
15›24 70 65 — —
25›44 252 157 22 16
45›64 90 74 163 152
>65 10 18 195 242
Total 451 356 380 410
Table 2 Mean number of reagent strips dispensed (95% confidence intervals) and
median (range) number by sex, age, duration of diabetes, and deprivation category
Detail
Type 1 diabetes Type 2 diabetes
Mean (95% CI) Median (range) Mean (95% CI) Median (range)
Total 659 (597 to 720) 300 (0›6220) 576 (519 to 634) 300 (0›10100)
Sex:
Male 611 (531 to 691) 300 (0›6220) 621 (523 to 719) 250 (0›10100)
Female 719 (623 to 815) 350 (0›5300) 535 (470 to 559) 300 (0›4300)
Age (years):
0›14 1148 (906 to 1390) 850 (0›5000) — —
15›24 444 (323 to 565) 200 (0›6220) — —
25›44 635 (548 to 721) 300 (0›6000) 1061 (593 to 1528) 300 (0›5400)
45›64 724 (581 to 866) 400 (0›4500) 687 (583 to 791) 400 (0›10100)
>65 419 (154 to 685) 50 (0›2450) 454 (396 to 513) 200 (0›4600)
Duration of diabetes (years):
0›4 980 (779 to 1182) 500 (0›6220) 759 (605 to 913) 400 (0›4300)
5›9 481 (373 to 588) 250 (0›5450) 515 (414 to 615) 250 (0›5400)
10›14 615 (473 to 758) 300 (0›4700) 504 (411 to 598) 300 (0›4600)
15›19 614 (454 to 775) 300 (0›4850) 509 (394 to 623) 250 (0›2850)
>20 637 (537 to 736) 350 (0›4500) 635 (435 to 836) 200 (0›10100)
Carstairs deprivation category:
1 706 (462 to 949) 375 (0›5000) 776 (525 to 1006) 400 (0›5400)
2 749 (592 to 906) 400 (0›6000) 660 (517 to 803) 350 (0›4600)
3 742 (613 to 872) 319 (0›6220) 578 (477 to 679) 300 (0›3550)
4 626 (480 to 772) 300 (0›5450) 497 (384 to 609) 250 (0›4500)
5 668 (494 to 842) 350 (0›4350) 587 (404 to 771) 250 (0›3800)
6 or 7 455 (334 to 575) 250 (0›5300) 520 (357 to 684) 200 (0›10100)
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adjust to type 1 diabetes. The decline in teenagers and
young adults, for whom parental control is presumably
less influential, however, is worrying and backs up pre›
vious work which showed that some are not even com›
pliant with insulin treatment.17 The Carstairs score is a
crude measure of social deprivation, but a link with
strip uptake was still evident, as has been documented
elsewhere for income and education level.5 Diabetic
patients do not pay for their prescriptions in the
United Kingdom so it is not that they cannot afford
them. The decline in self monitoring with age in
patients with type 1 and type 2 diabetes has also been
reported elsewhere.5
We believe that these results are reliable. Data from
the DARTS/MEMO collaboration are well vali›
dated.14 15 The dispensing of reagent strips was used as
a proxy measure for self monitoring, and, although
patients may not actually have used them (resulting in
overestimation of use), the misclassification effect of
primary non›compliance is eliminated,22 and the
method is probably more objective than direct
questioning of patients.23 We had no information on
strips dispensed to patients in hospitals, however, or on
glucose measurements performed by a third party (for
example, by district nurses).
Blood glucose control
The regression analysis suggested a direct association
between haemoglobin A1c concentration and the
number of strips obtained in a previous 6 month
period in patients with type 1 diabetes. This result indi›
cates either that self monitoring is important for main›
taining good diabetic control or that it is a proxy
measure of good health behaviour and practice that is
associated with good control. In other words, patients
who self monitor are also likely to be compliant with
their diabetic regimen, with confounding by factors
such as diet and exercise. When the analysis was
restricted to patients who obtained at least some strips
and could be regarded as partially compliant
(providing some control for confounding), however,
the association was still evident. Even if it is non›causal,
self monitoring might improve quality of life by giving
patients more control over their disease.4
The analysis could be carried out only for patients
who had haemoglobin A1c concentrations recorded
(predominately those residing in the geographical area
served by the main teaching hospital). This was not
dependent on the clinical characteristics of the patient
and is therefore unlikely to distort the results of the
study, and indeed the age and sex distributions of
patients with and without haemoglobin A1c concentra›
tions recorded were similar. Only one value was
analysed per patient as more regular readings might be
taken in patients judged to have poor control. Haemo›
globin A1c concentration is a biological correlate of dia›
betic control in the previous 3 months. The 6 month
period for obtaining strips was chosen to allow for
patients collecting them “in bulk” at infrequent intervals.
No association was found between haemoglobin
A1c concentration and self monitoring in patients with
type 2 diabetes who used insulin, as reported else›
where.12 It may be that blood glucose monitoring is
more effective in true insulin deficiency as opposed to
the insulin resistant state. Or patients with type 2
diabetes might be less familiar with insulin use, more
anxious about the risks of hypoglycaemia, and hence
less likely to act on the results of tests. It is also impor›
tant to note that patients with type 2 diabetes are a het›
erogeneous group, particularly in terms of pancreatic â
cell reserve. An alternative explanation for the study
findings is that self monitoring may be recommended
particularly in those patients who are the most difficult
to control.
Cost
The average cost of glucose monitoring per patient was
relatively low when compared with other costs
associated with diabetes care.24 Even for a patient who
is self monitoring four times daily, the approximate
cost per year is only £409. We therefore suggest that
self monitoring of blood glucose should be further
encouraged, particularly in those subgroups of patients
who do not monitor their blood glucose concentra›
tions regularly—for example, young deprived men with
type 1 diabetes.
Table 3 Linear regression models in 258 patients with type 1
diabetes with haemoglobin A1c concentration as outcome variable
Variable
Regression
coefficient P value
Univariate analysis
Age (+10 years) −0.097 0.156
Total strips dispensed (+180) −0.613 <0.001
Duration (+1 year) −0.006 0.539
Deprivation score (+1 category) 0.008 0.951
Sex (female v male) 0.474 0.025
Body mass index (+1 SD) −0.001 0.996
Adjusted analysis
Sex (female v male) 0.637 0.002
Total strips dispensed (+180) −0.661 <0.001
Table 4 Linear regression models in 290 patients with type 2
diabetes who were using insulin, with haemoglobin A1c
concentration as outcome variable
Factors in univariate analysis
Regression
coefficient P value
Age (+10 years) –0.0003 0.997
Total strips dispensed (+180) –0.108 0.357
Duration (+1 year) 0.007 0.616
Deprivation score (+1 category) –0.018 0.796
Sex (female v male) 0.217 0.283
Body mass index (+1 SD) 0.145 0.216
Key messages
+ Several studies have indicated the importance of self monitoring of
blood glucose concentration for prevention of complications in
patients with diabetes
+ Uptake of reagent strips for self monitoring of blood glucose
among diabetic patients who used insulin was low, with only 20%
of patients with type 1 diabetes and 17% of those with type 2
diabetes obtaining enough strips to test blood glucose
concentration once daily
+ Reagent strip uptake depends on characteristics such as age and
social deprivation category, and patient groups with low uptake
should be identified and targeted
+ There was a direct association between strip uptake in the previous
6 months and glycaemic control in patients with type 1 diabetes
but not in those with type 2 diabetes
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A memorable patient
“Thank you for ending 40 years of misery”
Mary, who is 85, has been my patient for about six years. In 1957
she had had a gastroenterostomy and vagotomy for a peptic
ulcer. Shortly afterwards, she had developed diarrhoea, which
became chronic—she had been referred to many clinics and had
been extensively investigated. No formal diagnosis seemed to
have been made although malabsorption, bile acid reflux,
postvagotomy diarrhoea, and dumping syndrome had been
considered at one time or another.
She had trials of a fat free diet, pancreatic supplements,
antibiotics, codeine, and bulking agents, but her bowels never
improved. She was told that diarrhoea was something she would
have to “put up with.” In 1995 she developed prolapsing piles for
which I referred her to hospital where she had a
haemorrhoidectomy. In 1996 I had written in the records
“chronic diarrhoea, for decades, recent faecal incontinence” and
had rereferred her—she ended up having a colonoscopy, which
was negative, and so she was discharged.
The diarrhoea was having a devastating impact on her life. In a
letter she subsequently sent me she wrote: “My bowels had gone
from bad to sheer hell. Not being able to go out without spending
a lot of time on the toilet before going out, having to find toilets
while out (very quickly) and in some cases having some very
embarrassing accidents while out. I must say it’s got to point
where I did not want to go out . . . even at home I had
accidents—going six times a day. Having mentioned this to so
many doctors in the past who said sorry but this is something that
I would have to put up with.”
During one consultation I thought that she might have
postvagotomy diarrhoea and suggested a trial of
cholestyramine.1 2 Within four weeks she had returned and stated
that she had had a good response to the treatment. I suggested
further referral and investigation, which she duly declined. At
review at 12 months and 18 months, her diarrhoea is still well
controlled.
She wrote about the impact of her new treatment: “Thank you
for ending 40 years of misery. I am only going to the toilet once a
day, I feel a lot better now in myself and I am now confident and
can go out when I want to. Without the worry, I feel 20 years
younger.”
In a busy surgery, faced with a patient with chronic problems, it
is easy to fall into the trap of thinking that a patient has been fully
investigated and that nothing more can be done. But it is
important to step back and reconsider. This is probably one of
the most important duties of a GP, who must remain responsible
for orchestrating the care of the patient and not be party to
“collusion of anonymity.” 3 Things that might help to recognise
the problem earlier include good record keeping and medical
summaries, unhurried consultations, and being constantly
receptive to the patient’s concerns.
1 Ayulo JA. Cholestyramine in postvagotomy syndrome. Amer J Gastroenterology
1972; 57:207›25.
2 Duncombe VM, Bolin TD, Davis AE. Double blind trial of cholestyramine in post›
vagotomy diarrhoea. Gut 1977;18:531›5.
3 Balint M. The doctor, his patient and the illness. 3rd edition. Edinburgh: Churchill
Livingstone, 1986.
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